Revenue ($USD) : $16,887,000,000
R&D spend : not available
Employees : not available
Fiscal year end : 12/31/2023
CEO : Robert Ford, chair and CEO; Lisa Earnhardt, EVP medical devices

www.abbott.com

Abbott medical device segment sales were up more than 12% during the first half of 2024. Diabetes treatment tech — especially the Abbott FreeStyle Libre continuous glucose monitor (CGM) — played an important role fueling the growth. FreeStyle Libre sales totaled $1.6 billion in the second quarter alone, marking 18.4% growth year-over-year. A new partnership to combine FreeStyle Libre CGM technology with Medtronic’s automated insulin delivery systems could boost sales even more in the years ahead. In June, Abbott announced that it secured FDA clearance for two over-the-counter CGM systems, Lingo and Libre Rio. Electrophysiology is also an exciting space for Abbott. The company in June announced CE mark approval for its Aveir DR dual-chamber leadless pacemaker system, nearly a year after Aveir won FDA approval. The company has seen recent launches and new indications for its Amplatzer Amulet, Navitor, and TriClip. When it comes to pulsed field ablation, Abbott continues to develop its Volt system, which has a ​​balloon-in-basket design meant to enable efficient deployment of energy into the tissue during cardiac ablation to treat AFib. –CN

MORE ON MDO: Design for access, says Abbott’s Lisa Earnhardt, medtech’s most powerful woman